A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Exclusion Criteria

• •Any primary psychiatric comorbid disorder
• •History of infantile spasms, West syndrome, Lennox-Gastaut syndrome, early infantile epileptic encephalopathy, treatment-refractory epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (CNS) infection
• •Seizure event of any type within 12 months prior to Screening or relevant changes in anti-epileptic drugs 6 weeks prior to enrollment
• •Significant sleep disruption
• •Significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease
• •New-onset or ongoing hematologic/oncologic disorder
• •Severe lactose intolerance
• •Participation in another clinical study within 1 month or 6 half-lives prior to first dose, or any extent of participation in Study BP29589 (NCT02451657)